FDA/SITC Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials Workshop
| When: Thursday, 11/8/2018 through Thursday, 11/8/2018, 2:00 pm - 6:00 pm |
|
|
|
Speakers:
 |
Jon M. Wigginton, MD |
Session I Panel Discussion |
3:10 pm - 3:55 pm |
 |
Sanjay Goel, MD |
Regulatory perspectives with use of immune-modified response criteria for assessment of surrogate clinical efficacy endpoints for registration trials |
2:30 pm - 2:50 pm |
 |
Rajeshwari Sridhara, PhD |
Beyond conventional tumor-based measurements: Analysis considerations for clinical efficacy endpoints to more fully capture the benefit of IO therapeutics |
4:30 pm - 4:50 pm |
 |
David F. McDermott, MD |
Clinical Trial Endpoints Considerations for Evaluating Efficacy in Immuno-Oncology Clinical Trials |
4:10 pm - 4:30 pm |
 |
David M. Feltquate, MD, PhD |
Session I Panel |
3:10 pm - 3:55 pm |
 |
Ke Liu, MD, PhD |
Session II Panel |
5:10 pm - 5:55 pm |
 |
Kim A. Margolin, MD |
Pseudoprogression and current clinical challenges in the management of patients on IO therapy |
2:10 pm - 2:30 pm |
 |
Peter Bross, MD |
Session I Panel |
3:10 pm - 3:55 pm |
 |
Howard L. Kaufman, MD, FACS |
Organizer |
2:00 pm - 6:00 pm |
 |
Marc Theoret, MD |
Organizer |
2:00 pm - 6:00 pm |
 |
Meredith Regan, PhD |
Session II Panel |
5:10 pm - 5:55 pm |
|
Lawrence H. Schwartz, MD |
Session II Panel |
5:10 pm - 5:55 pm |
|
Patricia Keegan, MD |
Regulatory perspectives with use of immune-modified response criteria for assessment of surrogate clinical efficacy endpoints for registration trials |
2:50 pm - 3:10 pm |
|
Reena Philip, PhD |
Session II Panel |
5:10 pm - 5:55 pm |
|
Steven Silverstein, MBA |
Session I Panel |
3:10 pm - 3:55 pm |
 |
Genevieve M. Boland, MD, PhD |
How to Integrate Biomarkers and Other Correlates of Response into the Regulatory Landscape |
4:50 pm - 5:10 pm |
 |
Samir N. Khleif, MD |
Session II Panel |
5:10 pm - 5:55 pm |
|